Obinutuzumab (Gazyva, Gazyvaro)

Description

Obinutuzumab is a glycoengineered, humanized monoclonal antibody that targets CD20-positive B cells. In colorectal cancer, obinutuzumab is being explored in combination regimens with other immunotherapies, particularly in microsatellite stable (MSS) tumors which typically respond poorly to immune checkpoint inhibitors alone. The drug is primarily established for treating certain blood cancers but is now being evaluated as part of multi-drug immunotherapy approaches for solid tumors including CRC.

Mechanism of Action

Obinutuzumab binds to the CD20 antigen expressed on B-lymphocytes and triggers both direct cell death and antibody-dependent cellular cytotoxicity (ADCC). In the colorectal cancer setting, the rationale involves depleting regulatory B cells that may suppress anti-tumor immune responses, potentially enhancing the efficacy of concurrent T-cell directed immunotherapies like bispecific antibodies and checkpoint inhibitors.

Molecular Targets

Side Effects

Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.

Clinical Trials